- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04243915
Percutaneous Neuromuscular Electrical Stimulation in Patients With Chronic Low Back Pain (PNMESlowback)
Effectiveness of Percutaneous Neuromuscular Electrical Stimulation on Lumbar Multifidus in Combination With a Protocol of Motor Control Exercises in Patients With Chronic Low Back Pain
Chronic low back pain is a common musculoskeletal condition affects the general population. Low back pain constitutes a major burden to health care system and society. Several authors have found that the deep abdominal muscles and multifidus are affected in low back pain. Dry needling has shown improve the cross-sectional area of the multifidus. Percutaneous electrical nerve stimulation has shown reduce pain in several conditions. There are not studies that had investigated the impact of percutaneous neuromuscular electrical stimulation (PNMES) in the deep muscles in patients with chronic low back pain.
Hypothesis: PNMES in the multifidus muscle plus motor control exercise program in patients with chronic low back pain is better than sham PNMES plus exercise and transcutaneous electrical nerve stimulation (TENS) plus exercise
Study Overview
Status
Conditions
Intervention / Treatment
- Other: Sham PNMES (introducing the needle) plus motor control exercise program
- Other: TENS plus motor control exercise program
- Other: Percutaneous neuromuscular electrical stimulation (PNMES) plus motor control exercise program
- Other: Sham PNMES (without inserting the needle) plus motor control exercise program
Detailed Description
Randomized, double-blind, placebo controlled clinical trial, using percutaneous neuromuscular electrical stimulation (PNMES). PNMES is technique to provide a transcutaneous electrical nerve stimulation current throughout needling filaments place close to the nerve.
Study Aims:
Aim #1: The primary aim of the study is to compare the effect of the short, medium and long-term of PNMES on muscle activation (increased cross-sectional area in activation) and the function of multifidus and abdominal transverse muscle in patients with chronic low back pain with random assignment to four treatments: PENS plus motor control exercise program or Sham PNMES (introducing the needle) plus motor control exercise program or Transcutaneous Electrical Nerve Stimulation (TENS) plus motor control exercise program or Sham PNMES (without inserting the needle) plus motor control exercise program.
Aim #2: The secondary aim of the study is to compare the effect of the short, medium and long-term of PNMES on pain as measured by visual analogue scale (VAS), chronic Pain Grade Questionnaire, pressure pain threshold (PPT), area and distribution of pain, conditioned pain modulation and temporal summation in patients with chronic low back pain with random assignment to four treatments: PNMES plus motor control exercise program or Sham PNMES (introducing the needle) plus motor control exercise program or Transcutaneous Electrical Nerve Stimulation (TENS) plus motor control exercise program or Sham PNMES (without inserting the needle) plus motor control exercise program.
Aim #3: To compare the effect of the short, medium and long-term of PNMES on disability as measured by Oswestry Disability Index, strength and quality of life with random assignment to four treatments: PENS plus motor control exercise program or Sham PNMES (introducing the needle) plus motor control exercise program or Transcutaneous Electrical Nerve Stimulation (TENS) plus motor control exercise program or Sham PNMES (without inserting the needle) plus motor control exercise program.
Aim #4: To estimate the immediate effects of the PNMES technique after the first session.
Aim #5: To determine if psychological factors (anxiety, depression, kinesiophobia and catastrophism) change with any of the treatments and if is related with the primary and secondary outcomes.
Aim #6: To evaluate the change perceived by the patient measured with Global Rating of Change Scale (GROC).
Aim Aim #7: Validation of placebo groups by assessing patient blindness
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Alberto Arribas-Roamno, MsC
- Phone Number: 635937520
- Email: albertoarribasromano@gmail.com
Study Locations
-
-
Madrid
-
Alcorcon, Madrid, Spain, 28922
- Recruiting
- Universidad Rey Juan Carlos
-
Contact:
- Josue Fernández-Carnero, PhD
- Phone Number: +34914888949
- Email: josue.fernandez@urjc.es
-
Principal Investigator:
- Josue Fernandez-Carnero, PhD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Low back pain more than 90 days of evolution
Exclusion Criteria:
- Spondylarthrosis
- History of fractures, luxations, surgery and/or musculoskeletal disorders in low back and lower limb.
- Leg pain or neuropathic pain (LANSS <12).
- Neurological disorders, inflammatory and/or degenerative diseases.
- Having received as treatment techniques that involve needles on the previous 6 months to study enrollment or having received percutaneous electrical stimulation as a treatment before.
- Physiotherapy treatment in the last 4 weeks.
- Specific lumbar pathology, fibromyalgia, unstable cardiovascular diseases, pregnant women or under suspect of pregnancy.
- Contraindications of needle's insertions: anticoagulant therapy, needle phobia, diabetes, hypothyroidism, lymphoedema, muscular diseases).
- Contraindications of electrical current.
- Drugs: morphine or opioids drugs.
- Depression
- Judicial dispute
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: PNMES plus exercise
6-week intervention program with 3 treatment sessions of PNMES and motor control exercise program.
|
Other: Percutaneous neuromuscular electrical stimulation (PNMES) plus motor control exercise program
The technique consists of a muscular stimulation of the deep lumbar multifidus by means of a TENS current applied through four dry needling or acupuncture needles introduced by ultrasound guidance in said muscle 30 minutes.
This will add to a protocol of motor control exercises for deep abdominal and lumbar muscles.
Other Names:
|
Sham Comparator: Sham PNMES (introducing the needle) plus exercise
Sham PNMES (introducing the needle) plus motor control exercise program
|
The same procedure will be performed as in the experimental treatment, but in this case, the electric current will be placebo and only the first 15 seconds will slightly notice it.
This will add to a protocol of motor control exercises for deep abdominal and lumbar muscles.
Other Names:
|
Active Comparator: TENS plus exercise
6-week intervention program with 3 treatment sessions of TENS plus motor control exercise program.
|
Transcutaneous electrical nerve stimulation will be applied through 4 patches / adhesives placed in your lower back for 30 minutes.
This will add to a protocol of motor control exercises for deep abdominal and lumbar muscles.
Other Names:
|
Placebo Comparator: Placebo PNMES (without inserting the needle) plus exercise
6-week intervention program with 3 treatment sessions of placebo PNMES (without inserting the needle) and exercise
|
The same procedure will be performed as in the experimental treatment, but in this case, the needle will not be inserted and the electric current will be placebo and only the first 15 seconds will slightly notice it.
This will add to a protocol of motor control exercises for deep abdominal and lumbar muscles.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Increased cross-sectional area in activation
Time Frame: Baseline, one hour from baseline after PNMES treatment 1, 6 weeks from baseline, 18 weeks from baseline and 30 weeks from baseline
|
The increase in height from the resting position to the submaximal contraction in the lumbar multifidus will be measured
|
Baseline, one hour from baseline after PNMES treatment 1, 6 weeks from baseline, 18 weeks from baseline and 30 weeks from baseline
|
Changes in the measurements of the multifidus and tranverse of the abdomen at rest.
Time Frame: Baseline, one hour from baseline after PNMES treatment 1, 6 weeks from baseline, 18 weeks from baseline and 30 weeks from baseline
|
Changes in the height of the multifidus at rest
|
Baseline, one hour from baseline after PNMES treatment 1, 6 weeks from baseline, 18 weeks from baseline and 30 weeks from baseline
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pain Grade Questionnaire
Time Frame: Baseline, 6 weeks from baseline, 18 weeks from baseline and 30 weeks from baseline
|
The scale assesses two dimensions: the intensity of pain and pain related to disability.
It can be used in any chronic pathology including musculoskeletal problems and low back pain.
It allows the graduation of the severity of chronic pain and the subsequent analysis of the qualitative changes for that pain.
The scale has 7 items, which are of the Likert type of 11 points, with a total range of 0 to 70 points.
|
Baseline, 6 weeks from baseline, 18 weeks from baseline and 30 weeks from baseline
|
Oswestry Disability Index or Oswestry Low Back Pain Disability Questionnaire
Time Frame: Baseline, 6 weeks from baseline, 18 weeks from baseline and 30 weeks from baseline
|
The Oswestry Disability Index (ODI) is a validated, self-reported instrument used by clinicians and researchers to quantify disability for low back pain. The self-completed questionnaire contains ten topics concerning intensity of pain, lifting, ability to care for oneself, ability to walk, ability to sit, sexual function, ability to stand, social life, sleep quality, and ability to travel. Each topic category is followed by 6 statements describing different potential scenarios in the patient's life relating to the topic. The patient then checks the statement which most closely resembles their situation. Each question is scored on a scale of 0-5 with the first statement being zero and indicating the least amount of disability and the last statement is scored 5 indicating most severe disability. The scores for all questions answered are summed, then multiplied by two to obtain the index (range 0 to 100). Zero is equated with no disability and 100 is the maximum disability possible. |
Baseline, 6 weeks from baseline, 18 weeks from baseline and 30 weeks from baseline
|
Short form 12 (SF-12) health survey (health-related quality of life)
Time Frame: Baseline, 6 weeks from baseline, 18 weeks from baseline and 30 weeks from baseline
|
The SF-12 is a validated, health-related quality-of-life questionnaire consisting of twelve questions that measure eight health domains to assess physical and mental health.
Physical health-related domains include General Health (GH), Physical Functioning (PF), Role Physical (RP), and Body Pain (BP).
Mental health-related scales include Vitality (VT), Social Functioning (SF), Role Emotional (RE), and Mental Health (MH).
The instrument has been validated across a number of chronic diseases and conditions.
The response options of the SF-12 v2 form Likert-type scales that evaluate intensity or frequency.
The number of answer options ranges from three to six, depending on the item, and each question is given a value which is then transformed into a scale from 0 to 100.
|
Baseline, 6 weeks from baseline, 18 weeks from baseline and 30 weeks from baseline
|
Kinesiophobia
Time Frame: Baseline, 6 weeks from baseline, 18 weeks from baseline and 30 weeks from baseline
|
Tampa Scale for Kinesiophobia.
To assess the fear of movement and pain-related fear.
The 11 items are scored 1-4, with total scores ranging from 11 to 44.
The addition of all the points obtained from each of the items results in the level of kinesiophobia, with higher scores indicating greater perceived kinesiophobia
|
Baseline, 6 weeks from baseline, 18 weeks from baseline and 30 weeks from baseline
|
Pain catastrophizing
Time Frame: Baseline, 6 weeks from baseline, 18 weeks from baseline and 30 weeks from baseline
|
Pain Catastrophizing Scale (PCS).
This tool is a 13-item questionnaire designed to measure the three components of pain-related catastrophizing: rumination, magnification, and helplessness, resulting in a unique score.
Each item is responded to on a 5-point scale (0 not at all, 4 all the time) relating the degree to which the individual experiences a thought or feeling of a painful situation.
|
Baseline, 6 weeks from baseline, 18 weeks from baseline and 30 weeks from baseline
|
The Becks Depression Inventory-II
Time Frame: Baseline, 6 weeks from baseline, 18 weeks from baseline and 30 weeks from baseline
|
The Becks Depression Inventory-II is a validated, self-administered questionnaire consisting of 21 multiple choice questions.
It is one of the most commonly used instruments to measure the severity of a depression.
Possible scores range from 0 (no depression) to 63 (severe depression).
|
Baseline, 6 weeks from baseline, 18 weeks from baseline and 30 weeks from baseline
|
Anxiety
Time Frame: Baseline, 6 weeks from baseline, 18 weeks from baseline and 30 weeks from baseline
|
The state-trait anxiety inventory (STAI) is a questionnaire that measures trait anxiety (a personality factor that predisposes the patient to suffer from anxiety) and the state of anxiety (environmental factors that protect or generate anxiety).
Each of the two sub-scales (trait anxiety and state anxiety) consists of 20 items, ranging from 0 (nothing) to 3 (a lot).
|
Baseline, 6 weeks from baseline, 18 weeks from baseline and 30 weeks from baseline
|
Intensity of Pain
Time Frame: (Baseline, one hour from baseline after PNMES treatment 1 (only at rest), 6 weeks from baseline, 18 weeks from baseline and 30 weeks from baseline
|
Will be measure with a line of 100 mmm (0 - no pain to 100- the worst pain) at rest and his best and worst pain in the last 24 hours.
|
(Baseline, one hour from baseline after PNMES treatment 1 (only at rest), 6 weeks from baseline, 18 weeks from baseline and 30 weeks from baseline
|
Pressure pain threshold using an algometer
Time Frame: Baseline, one hour from baseline after PNMES treatment 1, 6 weeks from baseline, 18 weeks from baseline and 30 weeks from baseline
|
Measurement of pressure pain threshold in the paravertebral muscles, in the spinous process of L4, and the tibialis anterior muscle.
|
Baseline, one hour from baseline after PNMES treatment 1, 6 weeks from baseline, 18 weeks from baseline and 30 weeks from baseline
|
Temporal summation
Time Frame: Baseline, one hour from baseline after PNMES treatment 1, 6 weeks from baseline, 18 weeks from baseline and 30 weeks from baseline
|
Ten consecutives pressure pain stimulus will be conducted, pain intensity in the first, fifth and tenth will be asked.
The difference from 1 to 10 will be the value that reports on the state of excitability of the posterior horn of the medulla
|
Baseline, one hour from baseline after PNMES treatment 1, 6 weeks from baseline, 18 weeks from baseline and 30 weeks from baseline
|
Conditioned pain modulation
Time Frame: Baseline, one hour from baseline after PNMES treatment 1, 6 weeks from baseline, 18 weeks from baseline and 30 weeks from baseline
|
First, pressure pain stimulus (test stimulus) will be conducted in the distal phalanx of the thumb.
Second, occlusion cuff will be inflated around the arm of patient until the patient feeling a painful intensity (conditioned stimulus) of 6/10.
Finally, after 30 seconds the stimulus will be done.
The difference in the mean value of the initial algometry with the mean value of algometry during the conditioning stimulus will indicate the state of the descending pain inhibitory system.
|
Baseline, one hour from baseline after PNMES treatment 1, 6 weeks from baseline, 18 weeks from baseline and 30 weeks from baseline
|
Global Rating of Change Scale
Time Frame: Baseline, 6 weeks from baseline, 18 weeks from baseline and 30 weeks from baseline
|
Global Rating of Change (GRoC) scales provide a means of measuring self-perceived change in health status.
Possible scores range from -5 (very much worse), through 0 (unchanged) to +5 (completely recovered).
|
Baseline, 6 weeks from baseline, 18 weeks from baseline and 30 weeks from baseline
|
Blinding the patient
Time Frame: 1 hour from baseline after the PNMES treatment 1, 2 weeks from baseline after the second PNMES treatment and 4 weeks from baseline after the third PNMES treatment
|
The patients of the sham groups will be asked after the interventions of PNMES if they belonged to the group of deep electro-stimulation, being able to content: Sure that yes, moderately that yes, I do not know, moderately that no or sure that no.
|
1 hour from baseline after the PNMES treatment 1, 2 weeks from baseline after the second PNMES treatment and 4 weeks from baseline after the third PNMES treatment
|
Central Sensitization Inventory
Time Frame: Baseline, 6 weeks from baseline, 18 weeks from baseline and 30 weeks from baseline
|
The Spanish version of the Central Sensitisation Inventory will be used to identify symptoms related to central sensitisation.
It is a self-report questionnaire that assesses a total of 25 sensitisation-associated symptoms on a 5-point Likert scale.
The total score ranges from 0 to 100, where >40/100 points suggest the presence of sensitisation-associated symptoms.
It has been found to have high reliability and validity.
|
Baseline, 6 weeks from baseline, 18 weeks from baseline and 30 weeks from baseline
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Josue Fernández-Carnero, PhD, Universidad Rey Juan Carlos
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- EC 01/2019
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Low Back Pain
-
Dow University of Health SciencesRecruitingLow Back Pain | Chronic Low-back Pain | Low Back Pain, Mechanical | Mechanical Low Back Pain | Pain, Chronic | Pain, Back | Lower Back Pain Chronic | CLBP - Chronic Low Back PainPakistan
-
Faculdade de Ciências Médicas da Santa Casa de...CompletedLow Back Pain, Mechanical | Low Back Pain, Postural | Lower Back Pain Chronic | Low Back Pain, Posterior CompartmentBrazil
-
University School of Physical Education in WroclawCompletedLow Back Pain | Low Back Pain, Mechanical | Low Back Pain, PosturalPoland
-
Texas Woman's UniversityTexas Physical Therapy AssociationCompletedLow Back Pain | Chronic Low Back Pain | Subacute Low Back PainUnited States
-
University of ParmaKing's College London; Helmholtz Zentrum München; GENOS; Ip Research Consulting... and other collaboratorsUnknownChronic Low Back Pain | Acute Low Back PainUnited States, Australia, Belgium, Croatia, Italy, United Kingdom
-
Ache Laboratorios Farmaceuticos S.A.Unknown
-
Palmer College of ChiropracticDepartment of Health and Human ServicesCompletedChronic Low Back Pain | Subacute Low Back PainUnited States
-
Universität Duisburg-EssenSiemens-BetriebskrankenkasseCompletedChronic Low Back Pain | Recurrent Low Back Pain
-
Karolinska InstitutetCompletedChronic Low Back Pain | Recurrent Low Back Pain | Persistent Low Back PainSweden
-
Apsen Farmaceutica S.A.CompletedLow Back Pain | Low Back Pain, Mechanical | Acute Low Back PainBrazil